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Abstract
Background: Maintaining endogenous testosterone (T) levels as men age may slow the symptoms of sarcopenia,
andropause and decline in physical performance. Drugs inhibiting the enzyme 5α-reductase (5AR) produce increased
blood levels of T and decreased levels of dihydrotestosterone (DHT). However, symptoms of gynecomastia have been
reported due to the aromatase (AER) enzyme converting excess T to estradiol (ES). The carotenoid astaxanthin (AX)
from Haematococcus pluvialis, Saw Palmetto berry lipid extract (SPLE) from Serenoa repens and the precise combination
of these dietary supplements, Alphastat® (Mytosterone(™)), have been reported to have inhibitory effects on both 5AR
and AER in-vitro. Concomitant regulation of both enzymes in-vivo would cause DHT and ES blood levels to decrease
and T levels to increase. The purpose of this clinical study was to determine if patented Alphastat® (Mytosterone(™))
could produce these effects in a dose dependent manner.
Methods: To investigate this clinically, 42 healthy males ages 37 to 70 years were divided into two groups of twenty-
one and dosed with either 800 mg/day or 2000 mg/day of Alphastat® (Mytosterone(™)) for fourteen days. Blood samples
were collected on days 0, 3, 7 and 14 and assayed for T, DHT and ES. Body weight and blood pressure data were
collected prior to blood collection. One-way, repeated measures analysis of variance (ANOVA-RM) was performed at
a significance level of alpha = 0.05 to determine differences from baseline within each group. Two-way analysis of variance
(ANOVA-2) was performed after baseline subtraction, at a significance level of alpha = 0.05 to determine differences
between dose groups. Results are expressed as means ± SEM.
Results: ANOVA-RM showed significant within group increases in serum total T and significant decreases in serum DHT
from baseline in both dose groups at a significance level of alpha = 0.05. Significant decreases in serum ES are reported
for the 2000 mg/day dose group and not the 800 mg/day dose group. Significant within group effects were confirmed
using ANOVA-2 analyses after baseline subtraction. ANOVA-2 analyses also showed no significant difference between
dose groups with regard to the increase of T or the decrease of DHT. It did show a significant dose dependant decrease
in serum ES levels.
Conclusion: Both dose groups showed significant (p = 0.05) increases in T and decreases in DHT within three days of
treatment with Alphastat® (Mytosterone(™)). Between group statistical analysis showed no significant (p = 0.05)
difference, indicating the effect was not dose dependent and that 800 mg/per day is equally effective as 2000 mg/day for
increasing T and lowering DHT. Blood levels of ES however, decreased significantly (p = 0.05) in the 2000 mg/day dose
group but not in the 800 mg/day dose group indicating a dose dependant decrease in E levels.
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Background
The process of male aging is associated with a slow pro-
gressive decrease in serum testosterone (T) levels as a
result of decreased production. It has been designated as T
deficiency syndrome (TDS) by the International Society of
Andrology (ISA), International Society for the Study of the
Aging Male (ISSAM) and European Association of Urol-
ogy (EAU) [1-3]. Its clinical features can be described as a
combination of sarcopenia and andropause leading to a
decline in physical performance [4]. Maintaining endog-
enous T levels as the male ages may slow the symptoms of
sarcopenia characterized by muscle erosion, loss of mus-
cle strength and bone mineral density. It may also play a
key role in eliminating the symptoms of andropause,
characterized by sexual dysfunction, lack of energy,
increased cognitive impairment and decreased general
well being [5-7]. Avoiding or slowing these symptoms is
important for staying healthy and competitive as life
expectancy increases. Many of them can be alleviated by T
replacement therapy either transdermally or by injection
however, they are only available by prescription because
of the potential risks of this treatment [5]. T is converted
to either dihydrotestosterone (DHT) by the enzyme 5α-
reductase (5AR) or estradiol (ES) by the aromatase (AER)
enzyme. Recent studies have shown that DHT adminis-
tered to orchidectomized mice resulted in increased high-
density lipoprotein cholesterol and triglyceride levels [8].
DHT is also implicated in the etiology of benign prostate
hyperplasia (BPH) which is regarded as a global health
problem in men over 50 years of age [9]. Elevated levels of
DHT, prostate specific antigen (PSA) and symptoms of
BPH are commonly treated with a 5AR inhibitor which
reduces the amount of T converted to DHT [10]. However,
5AR inhibitors produce increased blood levels of ES and
have been reported to cause symptoms of gynecomastia
[11]. Therefore, a dietary supplement that increases
endogenous levels of T while decreasing levels of DHT
and ES may be very useful for maintaining physical per-
formance and alleviating the conditions of andropause
and sarcopenia while decreasing the risk of BPH.
Recent in-vitro studies report that the carotenoid Astaxan-
thin (AX) from Haematococcus pluvialis is a more potent
inhibitor of 5AR than the Saw Palmetto berry lipid extract
(SPLE) from Serenoa repens. When AX is combined with
SPLE in specific amounts as (Mytosterone(™)), it showed
a greater inhibition of 5AR than SPLE alone [12]. Further,
in-vitro assays show that AX inhibits the AER enzyme
which converts T to ES [13]. Therefore, we hypothesize
that a precise combination of AX and SPLE, Alphastat®
(Mytosterone(™)), would regulate the inhibitory activity
of both 5AR and AR enzymes in-vivo. Concomitant regu-
lation of both enzymes would cause DHT and ES blood
levels to decrease and T levels to increase in a dose
dependant manner.
To investigate this, two groups of 21 healthy male partici-
pants between the ages of 40 and 70 years were dosed
with either 800 or 2000 mg of Alphastat®  (Mytoster-
one(™)) per day over a two week period. Serum levels of
T, DHT and ES were analyzed to determine changes in
hormone levels.
Methods
Study design
This design was a single centre, prospective, open-label,
dose comparison clinical study. Two groups of healthy,
male subjects were dosed with either 800 mg/day or 2000
mg/day of a precise combination of AX and SPLE (Alpha-
stat® (Mytosterone(™)), Triarco Industries, Wayne, NJ) for
14 consecutive days. Subjects were assigned to dose
groups in an alternating manner based on arrival time.
Serum levels of T, DHT and ES were used to investigate
differences between the two dose groups. Since the pur-
pose of the study was to compare the differences between
a high dose and a low dose from baseline values, a control
group was not used. Blood samples were drawn at approx-
imately the same time of day to minimize any diurnal var-
iations in hormone levels.
Subjects
Two groups of twenty-one healthy, males ages 37–70
years volunteered for this study. The ages of the 800 mg/
day dose group ranged from 37 years to 67 years with an
average of 55.6 years and body weight ranged from 68.4
kg to 102.5 kg with an average of 80.3 kg. The ages of the
2000 mg/day dose group ranged from 53 years to 70 years
with an average of 61 years and body weight ranged from
67.9 kg to 95.3 kg with an average of 84.8 kg. Inclusion
criteria required subjects to have a PSA lower than 10.1
ng/ml, and pass a compliance screening test and a health
screen for malaria, diabetes and ailments mentioned in
the exclusion criteria. Exclusion criteria included any cases
of moderately severe co-morbid disease including cardiac,
pulmonary, renal, hepatic, or active cancer, BPH with
complications, abnormal digital rectal examination
(DRE), active prostate cancer or history of acute bacterial
prostatitis. Also excluded were individuals taking, or who
had taken within the past 30 days, any dietary supple-
ments containing saw palmetto or astaxanthin. There
were no food or exercise requirements or restrictions. Par-
ticipants were advised and encouraged to maintain their
current dietary intake and exercise habits throughout the
study period to prevent changes in either from interfering
with the study results. This study was approved by the
University of Yaoundé I Teaching Hospital Review Board
and the Cameroon Research Ethics Committee. All sub-
jects enrolled in the study completed a written Institu-
tional Review Board (IRB)-approved informed consent
and were examined by an urologist at the hospital.Journal of the International Society of Sports Nutrition 2008, 5:12 http://www.jissn.com/content/5/1/12
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Dose protocol
The low dose group (n = 21) ingested two 400 mg cap-
sules per day, one in the morning and one in the evening.
The high dose group (n = 21) ingested five 400 mg cap-
sules per day, 2 in the morning, 1 in the afternoon and 2
in the evening. All capsules were taken with 8–12 oz of
water.
Diet
There were no diet protocol or diet log requirements how-
ever, participants were advised and encouraged to main-
tain their current dietary intake habits throughout the
study period in order to prevent changes in dietary intake
confounding the study results.
Sample collection
Blood samples were collected between 8 am and 10:30
AM on the sampling days. Sample collection was con-
ducted at the hospital using red capped Vacutainer® tubes
and centrifuged to produce serum. All tubes were coded,
refrigerated and sent to the Laboratory of Nutrition and
Nutritional Biochemistry for analyses.
Serum analyses
Serum levels of T, DHT, and ES were determined using
separate commercial ELISA test kits (Alpha Diagnostics,
San Antonio, USA). All reference standards, controls and
serum samples were dispensed at room temperature. All
test kits have been designed and tested for human serum
samples.
DHT determination in serum
A 50 μL aliquot of each standard, control and sample were
dispensed into separate antibody coated wells of the strip
plate. DHT – Horseradish peroxidase (HRP) conjugate
solution (100 μL) was then dispensed into each well, the
plates covered and incubated at room temperature for 60
minutes with gentle shaking. Following incubation the
plate was aspirated and washed three times with approxi-
mately 300 μL diluted wash buffer. HRP-substrate solu-
tion, Tetramethylbenzidine (TMB) (150 μL) was then
added into each well, the plates covered and incubated at
room temperature for 10 minutes with gentle shaking
(approximately 200 rpm) to develop a blue color. Stop-
ping solution (50 μL) was then added into each well and
the plates mixed gently as the blue color turned yellow.
The concentration of each well was determined by absorb-
ance measured at 450 nm. Within run variations in con-
trol values of greater than +/- 20% required reanalysis. The
specificity of DHT ELISA kit was determined by measuring
interference from high concentrations of the following:
DHT 100%; T, 8.7%; 5-beta-DHT, 2%; Androstenedione,
0.2%; Dehydroepiandrosterone sulfate, 17-beta-estradiol,
Estriol, Estrone, Progesterone, 17-OH-Progesterone, Cor-
tical pregnenolone < 0.01%.
ES determination in serum
A 50 μL aliquot of each standard, control and sample were
dispensed into separate anti-Mouse IgG coated wells of
the strip plate. ES-HRP conjugate solution (100 μL) was
then added into each well. The plate was covered and
incubated at room temperature for 60 minutes with gentle
shaking. Following incubation the plate was aspirated and
washed three times with approximately 250 μL diluted
wash buffer. HRP substrate, TMB solution (150 μL) was
added to each well, the plates covered and incubated at
room temperature for 10 minutes with gentle shaking to
develop a blue color. Stopping solution (50 μL) was then
added into each well and the plates mixed gently as the
blue color turned yellow. The concentration of each well
was determined by absorbance measured at 450 nm.
Within run variations in control values of greater than +/-
20% required reanalysis. The ES antibody used in this kit
is very sensitive and specific. The following compounds
were tested for cross reactivity of the assay: ES (100%),
Estriol and Estrone (1%), Progesterone, and Cortisol
(0.1%).
Total T determination in serum
A 10 μL aliquot of each standard, control and sample were
dispensed into the appropriate wells and rabbit polyclo-
nal antibody solution into all wells of the strip plate.
Enzyme conjugate solution (50 μL) was then added to
each well. The plate was covered and incubated at room
temperature for 60 minutes with gentle shaking. Follow-
ing incubation the plate was aspirated and washed 3 times
with approximately 250 μL diluted wash buffer. HRP sub-
strate Solution A (100 μL) and HRP substrate Solution B
(100 μL) was added to each well. The plate covered and
incubated at room temperature for 30 minutes with gentle
shaking. Stopping solution (50 μL) was then added into
each well and the plates mixed gently as the blue color
turned yellow. The concentration of each well was deter-
mined by absorbance measured at 450 nm. Within run
variations in control values of greater than +/- 20%
required reanalysis. The rabbit polyclonal antibody used
in this kit is very sensitive and specific for T. The following
compounds were tested for cross-reactivity of the assay: T
(100%), 5-a-dihydrostestosterone (9.6%), Androstenedi-
one (1.7%), 11-oxystestosterone (1.5%), Epiandroster-
one (0.06%). The following compounds had negligible
cross-reactivity: 5-beta-DHT, 5-a-androstan-3-a, 17b-
estradiol, 17b-Diol, 5-a-androstan-3, 17 dione, Andros-
terone, Cortisol, Dehydroepiandrosterone, Estriol,
Estrone, Progesterone, Corticosterone, Danazol, 11-b-
hydroxytestosterone.
Statistical analysis
All significance and power testing on results was done at a
level of alpha = 0.05. Within group analyses was per-
formed on T, DHT and ES levels between baseline andJournal of the International Society of Sports Nutrition 2008, 5:12 http://www.jissn.com/content/5/1/12
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each time point, within each dose group using one-way
repeated measures analysis of variance (ANOVA-RM).
Two-way analysis of variance (ANOVA-2) was performed
on T, DHT and ES levels between each dose group after
baseline subtraction. Results are expressed as means ±
SEM. Statistics were performed using a commercially
available software program (Origin® for Windows, version
8.0).
Results
Body weight and tolerance
The mean baseline body weight was 80.3 kg in the 800
mg/day dose group and 84.8 kg in the 2000 mg/day dose
group. There was no significant change in mean body
weight over the 14 day treatment period in either dose
group. Both doses of Alphastat® (Mytosterone(™)) were
well tolerated and no adverse events reported.
Blood pressure
The mean baseline systolic blood pressure (SBP) was 142
mmHg in the 800 mg/day dose group and 137 mmHg in
the 2000 mg/day dose group. No significant (p = 0.05)
changes in mean SBP from baseline values were reported
in the 800 mg/day dose group. In the 2000 mg/day group
SBP was reported to be significantly (p < 0.05) below
baseline values on day 3, day 7 and day 14. The mean
baseline Diastolic blood pressure (DBP) was 71.5 mmHg
in the 800 mg/day dose group and 66.9 mmHg in the
2000 mg/day dose group. DBP was reported to be signifi-
cantly (p < 0.05) below baseline values on day 7 and day
14 in both the 800 mg/day dose group and 2000 mg/day
dose group.
Serum T levels
The mean baseline level of serum total T in the 800 mg/
day dose group of 21.64 nmol/L was significantly (p =
0.05) different than the baseline level of 26.26 nmol/L in
the 2000 mg/day dose group. ANOVA-RM of the 800 mg/
day dose group showed the mean level of T was signifi-
cantly (p < 0.05) greater than the mean baseline level at
day 7 and day 14. ANOVA-RM of the 2000 mg/day dose
group showed the mean level of T was significantly (p <
0.05) greater than the mean baseline level at day 3, day 7
and day 14. ANOVA-2 comparison, after baseline subtrac-
tion, between the 800 mg/day dose group and the 2000
mg/day dose group showed the interaction between time
points to be significant (p = 0.05) reaching a statistical sig-
nificance of 1.0. Comparison of means between dose
groups showed no significant (p = 0.05) interaction reach-
ing a statistical power of 0.51 (Figure 1).
Serum DHT levels
The mean baseline level of serum DHT in the 800 mg/day
dose group of 2.79 nmol/L was significantly (p = 0.05)
different than the baseline level of 2.34 nmol/L in the
2000 mg/day dose group. ANOVA-RM of the 800 mg/day
dose group showed the mean level of DHT was signifi-
cantly (p < 0.05) less than the mean baseline level at day
3, day 7 and day 14. ANOVA-RM of the 2000 mg/day dose
group showed the mean level of DHT was significantly
Serum Total Testosterone Figure 1
Serum Total Testosterone. Effect of Alphastat® (Mytosterone(™)) on total testosterone levels (nmol/L). Values are means 
(+/- SEM), * indicates significant difference from baseline value (p ≤ 0.05).Journal of the International Society of Sports Nutrition 2008, 5:12 http://www.jissn.com/content/5/1/12
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less (p < 0.05) than the mean baseline level at day 3, day
7 and day 14. ANOVA-2 comparison, after baseline sub-
traction, between the 800 mg/day dose group and the
2000 mg/day dose group showed interaction between
time points to be significant (p = 0.05) reaching a statisti-
cal significance of 1.0. Comparison of means between
dose groups showed no significant (p = 0.05) interaction
reaching a statistical power of 0.46 (Figure 2).
Serum ES levels
The mean baseline level of serum ES in the 800 mg/day
dose group of 21.49 pmol/L was not significantly (p =
0.05) different than the baseline level of 23.94 pmol/L in
the 2000 mg/day dose group. ANOVA-RM of the 800 mg/
day dose group showed the mean level of ES was signifi-
cantly (p < 0.05) less than the mean baseline level at day
7. ANOVA-RM of the 2000 mg/day dose group showed
the mean level of ES was significantly less (p < 0.05) than
the mean baseline level at day 3, day 7 and day 14.
ANOVA-2 comparison, after baseline subtraction,
between the 800 mg/day dose group and the 2000 mg/day
dose group showed the interaction between time points to
be significant (p = 0.05) reaching a statistical significance
of 0.73. Interaction between dose groups was also signifi-
cant (p = 0.05) reaching a statistical power of 1.0 (Figure
3).
Discussion
ANOVA-RM analyses of the results show significant
increases in serum total T and significant decreases in
serum DHT in both dose groups as well as significant
decreases in serum ES in the 2000 mg/day dose group at a
significance level of alpha = 0.05. These significant differ-
ences from baseline were confirmed using ANOVA-2 anal-
yses after baseline subtraction. These results of increased T
levels with concurrent decreases in DHT and ES support
earlier in-vitro mechanism reports that the 5AR and AER
enzymes are inhibited by AX and SPLE [12,13]. They also
support the hypothesis that a precise combination of AX
and SPLE, Alphastat® (Mytosterone(™)), may regulate a
concomitant inhibitory activity of both enzymes in-vivo.
The doses used in this study however, did not result in a
clear dose dependent effect. ANOVA-2 analyses show no
significant difference between dose groups with regard to
the increase of T or the decrease of DHT. However, it did
show a significant dose dependant decrease in serum ES
levels. The lack of a dose response with regard to T and
DHT indicates the maximum effect of Alphastat® (Myto-
sterone(™)) is obtained at the 800 mg/day dose. Further
studies using lower doses must be conducted to establish
a dose response and maximum effect level regarding T and
ES. A dose of 2000 mg/day may be necessary if decreases
in ES levels are desired. This effect may have an applica-
tion in women that are prone to estrogen dependent
breast cancer and requires further exploration.
The results also suggest that Alphastat® (Mytosterone(™))
is equally effective in men between the ages of 37 and 70
for increasing endogenous total serum T levels and
Serum Dihydrotestosterone Figure 2
Serum Dihydrotestosterone. Effect of Alphastat® (Mytosterone(™)) on serum DHT levels (nmol/L). Values are means (+/- 
SEM), *indicates significant difference from baseline value (p ≤ 0.05).Journal of the International Society of Sports Nutrition 2008, 5:12 http://www.jissn.com/content/5/1/12
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decreasing serum DHT levels without increasing ES levels.
The 800 mg/day dose group ranged 37 – 67 years with a
mean of 55.5 years and 24% under the age of 50. The
2000 mg/day dose group ranged 53 – 70 years with a
mean of 61 years and no one under the age of 50. Confir-
mation of this by further studies is important since mean
total T levels have been reported to decrease by 30%
between the ages of 25 and 75 [14]. The decline in T as a
result of male aging is designated as TDS by several inter-
national societies and is described as a combination of
sarcopenia and andropause [1-3]. Its clinical features are
characterized by muscle erosion, loss of muscle strength
and bone mineral density as well as increased sexual dys-
function, lack of energy, increased cognitive impairment
and decreased general well being [5-7]. Avoiding or slow-
ing these symptoms is important for staying healthy and
competitive as life expectancy increases. The results of this
study indicate that Alphastat® (Mytosterone(™)) may help
maintain or reverse declining T levels in the aging male by
maintaining endogenous T levels and without increasing
ES levels. It may also be beneficial in males prone to
developing symptoms of BPH due to elevated DHT levels.
BPH is regarded as a global health problem in men with
approximately 50% of men over age 50 reporting symp-
toms [9,10]. Alphastat® (Mytosterone(™)) may regulate
DHT levels without the side effects of increased ES levels
reported with the use of prescription drugs that inhibit
5AR.
Conclusion
The precise combination of AX and SPLE, Alphastat®
(Mytosterone(™)), produced significant changes in serum
T, DHT and ES levels. A dose of either 800 mg or 2000 mg/
day produced significant increases in T and decreases in
DHT within three days with no increases in ES. The effect
was not dose dependent indicating that the 800 mg/per
day dose is as equally effective as 2000 mg/day in the age
range of subjects studied. Blood levels of ES also decreased
significantly and in a dose dependant manner indicating
the 2000 mg/day dose is more effective than the 800 mg/
day dose. There were no outward signs of toxicity or
adverse reactions. This data provides support for each
mechanism of action observed in-vitro and suggests a
potential role for its use in aging men experiencing TDS or
symptoms of BPH.
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